The EGF component includes an EGF, and preferably a human EGF.

Activation of EGF receptor by EGF via the formation of

Further, antisense oligonucleotides targeted to a mutant EGF receptor which decreases expression of a mutant EGF receptor are disclosed.

Cancer cells that have the EGFR mutation are called EGFR positive (EGFR+).

Structure of heparin-binding EGF-like growth factor.

The method of claim 1, wherein the EGF is human EGF or recombinant human EGF.

Heparin-binding EGF-like growth factor (HB-EGF) belongs to the EGF family of

First of all, EGF stands for Epidermal Growth Factor.

The present invention relates to combination therapies for the treatment of EGFR-related diseases, particularly EGFR-related cancers.

EGFR+ means that the cancer cells have the EGFR mutation.

Thus, disclosed is a monoclonal antibody capable of binding to an HB-EGF that is bound to a cell membrane, a membrane-anchored HB-EGF and a secreted HB-EGF or a fragment of the monoclonal antibody.

The invention involved the use of mitogenic factor ---EGF and bFGF.

Polypeptides comprising EGFR extracellular domains I-III capable of forming dimeric EGF-binding proteins are provided.

Disclosed is a monoclonal antibody capable of binding to an HB-EGF binding to a cell membrane, a membrane-anchored HB-EGF or a secreted HB-EGF or a fragment of the antibody.

growth factors, such as the heparin-binding EGF-like growth factor (HB-